Latest Articles

Publication Date
Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Endometriosis is a chronic gynecological condition commonly associated with pelvic pain, dysmenorrhea, dyspareunia, and infertility. Owing to the limitations and adverse effects of traditional hormonal therapies, this study aimed to …

Published: Sept. 12, 2025, midnight
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com

Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com

Published: Aug. 20, 2025, 3:46 a.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail

Published: Aug. 6, 2025, 1:11 p.m.
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Disparities in Racial and Ethnic Representation in Clinical Trials for FDA-Approved Treatments of Endometriosis.

Published: July 23, 2025, midnight
The Role of Plant-Based Diets and Personalized Nutrition in Endometriosis Management: A Review.

Endometriosis is a chronic, estrogen-dependent inflammatory condition that affects multiple organ systems and significantly impairs the quality of life in women of reproductive age. While conventional hormonal therapies may alleviate …

Published: July 13, 2025, midnight
Endometriosis market expected to reach $2.5bn across 7MM by 2034 - Clinical Trials Arena

Endometriosis market expected to reach $2.5bn across 7MM by 2034 Clinical Trials Arena

Published: July 1, 2025, 9:11 a.m.
Childhood traumatic events associated with endometriosis risk - Clinical Trials Arena

Childhood traumatic events associated with endometriosis risk Clinical Trials Arena

Published: June 17, 2025, 9:27 a.m.
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer - Clinical Trials Arena

Daiichi announces first subject dosing in Enhertu trial for endometrial cancer Clinical Trials Arena

Published: June 10, 2025, 9:06 a.m.
Endometriosis linked with increased risk of autoimmune disease - Clinical Trials Arena

Endometriosis linked with increased risk of autoimmune disease Clinical Trials Arena

Published: May 23, 2025, 3:24 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!